{
    "clinical_study": {
        "@rank": "102536", 
        "arm_group": [
            {
                "arm_group_label": "Drug (Standard group)", 
                "arm_group_type": "Other", 
                "description": "Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.\nCiprofloxacin 500mg by mouth twice a day for three days."
            }, 
            {
                "arm_group_label": "Intervention group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration\nOral Placebo, one cap twice a day for three days."
            }
        ], 
        "brief_summary": {
            "textblock": "Our hypothesis is that a single dose of antibiotics at time of EUS-guided pancreatic cyst\n      aspiration is equally effective to the usual regimen of 3 days of post-procedural\n      antibiotics."
        }, 
        "brief_title": "A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration", 
        "condition": "Pancreatic Cysts", 
        "condition_browse": {
            "mesh_term": [
                "Cysts", 
                "Pancreatic Cyst"
            ]
        }, 
        "detailed_description": {
            "textblock": "With the increased use of cross sectional imaging, there appears to be an increasing\n      prevalence of pancreatic cysts being incidentally discovered.\n\n      A critical step in the workup of pancreas cysts is to determine whether the cyst is mucinous\n      or non-mucinous, through a procedure called endoscopic ultrasound - fine needle aspiration\n      (EUS-FNA).\n\n      Current guidelines suggest the use of antibiotics in cyst aspiration, usually 3 days after\n      the procedure.  However, these recommendations are based on limited data from over 15 years\n      ago.  More recent retrospective observations suggest equivalent safety when little, or even\n      no antibiotics are given."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients between the age of 18-90 who present for an EUS / pancreas cyst evaluation\n\n        Exclusion Criteria:\n\n          -  Patients outside the age range\n\n          -  Patient-related factors (unable to provide consent, unable to understand English,\n             allergic to cipro)\n\n          -  High-risk patients for infective endocarditis\n\n          -  Bacterial infection or use of antibiotics within 6 weeks of EUS\n\n          -  Pancreatitis within the past 6 months\n\n          -  Underlying immunosuppression (for example, uncontrolled diabetes - such as hemoglobin\n             A1c above 7 or glucose > 180; renal failure; cirrhosis; pre-existing malignancy\n             especially hematologic malignancy such as leukemia / lymphoma / multiple myeloma;\n             HIV/AIDS)\n\n          -  Currently taking immunosuppressive medications (for conditions such as rheumatoid\n             arthritis, inflammatory bowel disease, organ transplant)\n\n          -  Radiographic or endosonographic evidence of cyst cavity debris / necrotic debris\n\n          -  Severe systemic disease (for example, NYHA class III or IV heart failure,\n             oxygen-dependent COPD)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929460", 
            "org_study_id": "1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Drug (Standard group)", 
                "intervention_name": "Ciprofloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Cipro"
            }, 
            {
                "arm_group_label": "Intervention group", 
                "intervention_name": "Placebo (for ciprofloxacin)", 
                "intervention_type": "Other", 
                "other_name": "sugar pill formulated to mimic oral ciprofloxacin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular", 
                "Ciprofloxacin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "email": "stephanie.x.tovar@kp.org", 
                "last_name": "Karl Kwok, MD", 
                "phone": "323-783-6830"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90027"
                }, 
                "name": "Kaiser Permanente, Los Angeles Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Placebo-controlled Trial on the Use of Antibiotics for Pancreatic Cyst Aspiration: a Pilot Study", 
        "overall_contact": {
            "email": "stephanie.x.tovar@kp.org", 
            "last_name": "Karl Kwok, MD", 
            "phone": "323-783-6830"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "first time point", 
                "measure": "Number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration", 
                "safety_issue": "No", 
                "time_frame": "At 2 weeks after procedure"
            }, 
            {
                "description": "second time point", 
                "measure": "Number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration", 
                "safety_issue": "No", 
                "time_frame": "At 4 weeks after procedure"
            }, 
            {
                "description": "third and final time point", 
                "measure": "Number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration", 
                "safety_issue": "No", 
                "time_frame": "At 6 weeks after procedure"
            }
        ], 
        "reference": [
            {
                "PMID": "15758904", 
                "citation": "Jacobson BC, Baron TH, Adler DG, Davila RE, Egan J, Hirota WK, Leighton JA, Qureshi W, Rajan E, Zuckerman MJ, Fanelli R, Wheeler-Harbaugh J, Faigel DO; American Society for Gastrointestinal Endoscopy. ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc. 2005 Mar;61(3):363-70."
            }, 
            {
                "PMID": "15765442", 
                "citation": "Lee LS, Saltzman JR, Bounds BC, Poneros JM, Brugge WR, Thompson CC. EUS-guided fine needle aspiration of pancreatic cysts: a retrospective analysis of complications and their predictors. Clin Gastroenterol Hepatol. 2005 Mar;3(3):231-6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929460"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaiser Permanente", 
            "investigator_full_name": "Karl Kwok", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "1. adverse drug reactions", 
                "measure": "Secondary outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "six weeks"
            }, 
            {
                "description": "2. procedure-related complications", 
                "measure": "secondary outcome", 
                "safety_issue": "Yes", 
                "time_frame": "six weeks"
            }, 
            {
                "description": "3. performance of cyst fluid markers for classification of mucinous cystic lesions", 
                "measure": "secondary outcome", 
                "safety_issue": "No", 
                "time_frame": "six weeks"
            }
        ], 
        "source": "Kaiser Permanente", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaiser Permanente", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}